These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 17659339)

  • 1. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
    Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
    Koschny R; Holland H; Sykora J; Haas TL; Sprick MR; Ganten TM; Krupp W; Bauer M; Ahnert P; Meixensberger J; Walczak H
    Clin Cancer Res; 2007 Jun; 13(11):3403-12. PubMed ID: 17545549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
    Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
    Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
    Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
    Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
    Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
    Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
    Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
    Canestraro M; Galimberti S; Savli H; Palumbo GA; Tibullo D; Nagy B; Guerrini F; Piaggi S; Cine N; Metelli MR; Petrini M
    Cancer Genet Cytogenet; 2010 Jun; 199(2):110-20. PubMed ID: 20471514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
    Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
    Chu S; Alexiadis M; Fuller PJ
    Reprod Sci; 2009 Apr; 16(4):397-407. PubMed ID: 19087975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.
    Ko BS; Chang TC; Chen CH; Liu CC; Kuo CC; Hsu C; Shen YC; Shen TL; Golubovskaya VM; Chang CC; Shyue SK; Liou JY
    Life Sci; 2010 Jan; 86(5-6):199-206. PubMed ID: 20006625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
    Lauricella M; Emanuele S; D'Anneo A; Calvaruso G; Vassallo B; Carlisi D; Portanova P; Vento R; Tesoriere G
    Apoptosis; 2006 Apr; 11(4):607-25. PubMed ID: 16528474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
    Shringarpure R; Catley L; Bhole D; Burger R; Podar K; Tai YT; Kessler B; Galardy P; Ploegh H; Tassone P; Hideshima T; Mitsiades C; Munshi NC; Chauhan D; Anderson KC
    Br J Haematol; 2006 Jul; 134(2):145-56. PubMed ID: 16846475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
    Smith MR; Jin F; Joshi I
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor].
    Fu YB; Sun QX; Meng FY; Xie J; Zhou GB
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2413-6. PubMed ID: 17156654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
    Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
    Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2.
    Siegelin MD; Gaiser T; Habel A; Siegelin Y
    Cancer Lett; 2009 Oct; 283(2):230-8. PubMed ID: 19398149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
    Srimatkandada P; Loomis R; Carbone R; Srimatkandada S; Lacy J
    Eur J Haematol; 2008 May; 80(5):407-18. PubMed ID: 18221384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.